Влодавец Дмитрий Владимирович
Pirogov Russian National Research Medical University · 124 works · 1,458 citations · h-index 14
Top works
- Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
- Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
- Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
- Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
- Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
- MRI in sarcoglycanopathies: a large international cohort study
- Risdiplam in Presymptomatic Spinal Muscular Atrophy
- SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)
- Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia
- FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)
- Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
- Targeted therapy for tuberous sclerosis complex
- FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)
- The efficacy and safety of nusinersen within the expanded access program in Russia
- Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries
- CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene
- RAINBOWFISH: Preliminary Efficacy and Safety Data in Risdiplam-Treated Infants with Presymptomatic SMA (P17-5.003)
- The social-economic burden of spinal muscular atrophy in Russia
- Pilot Program of Newborn Screening for 5q Spinal Muscular Atrophy in the Russian Federation
- FP.24 RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)